Abstract:
The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.
Abstract:
Quinazolines of the formula I in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
Abstract:
The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
Abstract:
Quinazolines of the formula (I) in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
Abstract:
The invention relates to compounds of Formula I: wherein A is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORA, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; or a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; R1 is —H, aryl, —CORa, —CORa, —COORa, —CONRaRb, —SO2Ra or —SO2NRaRb; X is —CO—, —C(═NH)—, —CS—, —CON(Ra)—, —CS(NRa)—, —SO2— or —CRaRb—; Y is —S—, —SO—, —SO2—, —O— or direct link; R2 is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which may be optionally substituted with one or more halogens; and W is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C1-4 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, —CF3, alkoxy, aryloxy, arylalkoxy, —OCF3, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —NHCORaRb, —NHSO2Ra, —NO2, —SORa, —SO3Ra or —SO2NRaRb; or a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —OCO-alkylamino, —OCO-alkylamido, CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
Abstract:
Businesses with a number of clients have a need to allocate communication costs to the client on whose behalf the costs were incurred. This invention provides a means whereby the telecommunication carrier can charge call costs originating from a single line 2 to one of a plurality of accounts 8 selected by the user of the phone 1. At the exchange 3, a flag 5 associated with line 2 notifies the processor 6 that an account A/C No must be selected before a call can be made via line 2. A Recorded Voice Message (RVM) or specific dial tone is sent to the user of the phone 1 to notify him of the need to select an account (optionally after entering a PIN). When the user selects the account, the line 2 is enabled to initiate a call through the network via switch 4. The processor 6 charges the cost for the call to the selected account.
Abstract:
The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
Abstract:
The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
Abstract:
A system and method are provided for securely buffering overhead messages in a network-connected integrated circuit. The method comprises: receiving messages including overhead bytes; collecting overhead bytes; creating a first overhead message from the collected overhead bytes; establishing a overhead message semaphore; and, saving the first overhead message until it is read, in response to the semaphore. Saving the first overhead message until it is read means not overwriting the first overhead message stored in the buffer until the buffer is read. Not overwriting the first overhead message stored in the buffer until the buffer is read includes the substeps of: setting the semaphore to the lock state; and, in response the semaphore lock state, not writing collected overhead bytes for a second overhead message to the buffer.
Abstract:
A system and method are provided for generating alarms from forward error correction (FEC) data in a G.709 network-connected integrated circuit. The method includes: receiving messages including forward error correction bytes; using the forward error correction bytes to detect errors in the messages; and, generating alarm signals in response to the detected errors. Generating alarm signals in response to the detected errors includes generating a signal degrade (SD) signal in response to detecting a first number of errors (error density) within a predetermined time period. Likewise, generating alarm signals in response to the detected errors includes generating a signal fail (SF) signal in response to detecting a second number of errors (second error density), greater than the first number, within the predetermined time period. The method further includes: selecting an error type. Then, alarm signals are generated in response to the selected error type. The error types include a “1s” density alarm, a “0s” density alarm, a bytes density alarm, and a sub-row density alarm.